BEVERLY, Mass. – Nov. 1, 2022 – Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced top-line clinical results for its Phase II COVID-19 “universal” booster vaccine, AKS-452. An interim analysis of the data found that 93% of subjects previously vaccinated with Pfizer, Moderna, Johnson & Johnson (Janssen), and AstraZeneca vaccines showed an increase in neutralizing antibody titers after receiving a single dose of AKS-452. The average neutralization titers across all subjects increased 4-fold against the Wuhan strain and 5-fold against the Omicron variants at Day 28. There were no safety issues reported.

Click here to read the full press release.